The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Invasive Cancer Diagnostics Market Research Report 2025
Synopsis
Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.
The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization’s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.
The global Non-Invasive Cancer Diagnostics market was valued at US$ 108520 million in 2023 and is anticipated to reach US$ 146340 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Invasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Invasive Cancer Diagnostics.
Report Scope
The Non-Invasive Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Invasive Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Invasive Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Segment by Type
CTCs
CTNAS
Exosomes
Segment by Application
Blood
Urine
Saliva
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Invasive Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.
The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization’s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.
The global Non-Invasive Cancer Diagnostics market was valued at US$ 108520 million in 2023 and is anticipated to reach US$ 146340 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Invasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Invasive Cancer Diagnostics.
Report Scope
The Non-Invasive Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Invasive Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Invasive Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Segment by Type
CTCs
CTNAS
Exosomes
Segment by Application
Blood
Urine
Saliva
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Invasive Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Invasive Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CTCs
1.2.3 CTNAS
1.2.4 Exosomes
1.3 Market by Application
1.3.1 Global Non-Invasive Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood
1.3.3 Urine
1.3.4 Saliva
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Invasive Cancer Diagnostics Market Perspective (2019-2030)
2.2 Non-Invasive Cancer Diagnostics Growth Trends by Region
2.2.1 Global Non-Invasive Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Invasive Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Non-Invasive Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Non-Invasive Cancer Diagnostics Market Dynamics
2.3.1 Non-Invasive Cancer Diagnostics Industry Trends
2.3.2 Non-Invasive Cancer Diagnostics Market Drivers
2.3.3 Non-Invasive Cancer Diagnostics Market Challenges
2.3.4 Non-Invasive Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Invasive Cancer Diagnostics Players by Revenue
3.1.1 Global Top Non-Invasive Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Non-Invasive Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Non-Invasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Invasive Cancer Diagnostics Revenue
3.4 Global Non-Invasive Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Non-Invasive Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Invasive Cancer Diagnostics Revenue in 2023
3.5 Non-Invasive Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Non-Invasive Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Non-Invasive Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Invasive Cancer Diagnostics Breakdown Data by Type
4.1 Global Non-Invasive Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Non-Invasive Cancer Diagnostics Breakdown Data by Application
5.1 Global Non-Invasive Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Invasive Cancer Diagnostics Market Size (2019-2030)
6.2 North America Non-Invasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Invasive Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Non-Invasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Non-Invasive Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Invasive Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Non-Invasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Non-Invasive Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gen-Probe Inc
11.1.1 Gen-Probe Inc Company Detail
11.1.2 Gen-Probe Inc Business Overview
11.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Introduction
11.1.4 Gen-Probe Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.1.5 Gen-Probe Inc Recent Development
11.2 Digene Corporation
11.2.1 Digene Corporation Company Detail
11.2.2 Digene Corporation Business Overview
11.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Introduction
11.2.4 Digene Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.2.5 Digene Corporation Recent Development
11.3 Quest Diagnostics Inc
11.3.1 Quest Diagnostics Inc Company Detail
11.3.2 Quest Diagnostics Inc Business Overview
11.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Introduction
11.3.4 Quest Diagnostics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.3.5 Quest Diagnostics Inc Recent Development
11.4 Cancer, Genetics Inc
11.4.1 Cancer, Genetics Inc Company Detail
11.4.2 Cancer, Genetics Inc Business Overview
11.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Introduction
11.4.4 Cancer, Genetics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.4.5 Cancer, Genetics Inc Recent Development
11.5 BIOVIEW Inc
11.5.1 BIOVIEW Inc Company Detail
11.5.2 BIOVIEW Inc Business Overview
11.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Introduction
11.5.4 BIOVIEW Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.5.5 BIOVIEW Inc Recent Development
11.6 AVIVA Biosciences Corporation
11.6.1 AVIVA Biosciences Corporation Company Detail
11.6.2 AVIVA Biosciences Corporation Business Overview
11.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Introduction
11.6.4 AVIVA Biosciences Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.6.5 AVIVA Biosciences Corporation Recent Development
11.7 Laboratory Corporation of America Holdings (LabCorp)
11.7.1 Laboratory Corporation of America Holdings (LabCorp) Company Detail
11.7.2 Laboratory Corporation of America Holdings (LabCorp) Business Overview
11.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Introduction
11.7.4 Laboratory Corporation of America Holdings (LabCorp) Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.7.5 Laboratory Corporation of America Holdings (LabCorp) Recent Development
11.8 A&G Pharmaceutical
11.8.1 A&G Pharmaceutical Company Detail
11.8.2 A&G Pharmaceutical Business Overview
11.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Introduction
11.8.4 A&G Pharmaceutical Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.8.5 A&G Pharmaceutical Recent Development
11.9 Affymetrix Inc
11.9.1 Affymetrix Inc Company Detail
11.9.2 Affymetrix Inc Business Overview
11.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Introduction
11.9.4 Affymetrix Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.9.5 Affymetrix Inc Recent Development
11.10 Precision Therapeutics
11.10.1 Precision Therapeutics Company Detail
11.10.2 Precision Therapeutics Business Overview
11.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Introduction
11.10.4 Precision Therapeutics Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024)
11.10.5 Precision Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Non-Invasive Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of CTCs
Table 3. Key Players of CTNAS
Table 4. Key Players of Exosomes
Table 5. Global Non-Invasive Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-Invasive Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Non-Invasive Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Non-Invasive Cancer Diagnostics Market Share by Region (2019-2024)
Table 9. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Non-Invasive Cancer Diagnostics Market Share by Region (2025-2030)
Table 11. Non-Invasive Cancer Diagnostics Market Trends
Table 12. Non-Invasive Cancer Diagnostics Market Drivers
Table 13. Non-Invasive Cancer Diagnostics Market Challenges
Table 14. Non-Invasive Cancer Diagnostics Market Restraints
Table 15. Global Non-Invasive Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Non-Invasive Cancer Diagnostics Market Share by Players (2019-2024)
Table 17. Global Top Non-Invasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Invasive Cancer Diagnostics as of 2023)
Table 18. Ranking of Global Top Non-Invasive Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Non-Invasive Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Non-Invasive Cancer Diagnostics Product Solution and Service
Table 22. Date of Enter into Non-Invasive Cancer Diagnostics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Non-Invasive Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 26. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 28. Global Non-Invasive Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 30. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 32. North America Non-Invasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Non-Invasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Non-Invasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Gen-Probe Inc Company Detail
Table 48. Gen-Probe Inc Business Overview
Table 49. Gen-Probe Inc Non-Invasive Cancer Diagnostics Product
Table 50. Gen-Probe Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 51. Gen-Probe Inc Recent Development
Table 52. Digene Corporation Company Detail
Table 53. Digene Corporation Business Overview
Table 54. Digene Corporation Non-Invasive Cancer Diagnostics Product
Table 55. Digene Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 56. Digene Corporation Recent Development
Table 57. Quest Diagnostics Inc Company Detail
Table 58. Quest Diagnostics Inc Business Overview
Table 59. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product
Table 60. Quest Diagnostics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 61. Quest Diagnostics Inc Recent Development
Table 62. Cancer, Genetics Inc Company Detail
Table 63. Cancer, Genetics Inc Business Overview
Table 64. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product
Table 65. Cancer, Genetics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 66. Cancer, Genetics Inc Recent Development
Table 67. BIOVIEW Inc Company Detail
Table 68. BIOVIEW Inc Business Overview
Table 69. BIOVIEW Inc Non-Invasive Cancer Diagnostics Product
Table 70. BIOVIEW Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 71. BIOVIEW Inc Recent Development
Table 72. AVIVA Biosciences Corporation Company Detail
Table 73. AVIVA Biosciences Corporation Business Overview
Table 74. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product
Table 75. AVIVA Biosciences Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 76. AVIVA Biosciences Corporation Recent Development
Table 77. Laboratory Corporation of America Holdings (LabCorp) Company Detail
Table 78. Laboratory Corporation of America Holdings (LabCorp) Business Overview
Table 79. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product
Table 80. Laboratory Corporation of America Holdings (LabCorp) Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 81. Laboratory Corporation of America Holdings (LabCorp) Recent Development
Table 82. A&G Pharmaceutical Company Detail
Table 83. A&G Pharmaceutical Business Overview
Table 84. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product
Table 85. A&G Pharmaceutical Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 86. A&G Pharmaceutical Recent Development
Table 87. Affymetrix Inc Company Detail
Table 88. Affymetrix Inc Business Overview
Table 89. Affymetrix Inc Non-Invasive Cancer Diagnostics Product
Table 90. Affymetrix Inc Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 91. Affymetrix Inc Recent Development
Table 92. Precision Therapeutics Company Detail
Table 93. Precision Therapeutics Business Overview
Table 94. Precision Therapeutics Non-Invasive Cancer Diagnostics Product
Table 95. Precision Therapeutics Revenue in Non-Invasive Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 96. Precision Therapeutics Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Invasive Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Invasive Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. CTCs Features
Figure 4. CTNAS Features
Figure 5. Exosomes Features
Figure 6. Global Non-Invasive Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Non-Invasive Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 8. Blood Case Studies
Figure 9. Urine Case Studies
Figure 10. Saliva Case Studies
Figure 11. Non-Invasive Cancer Diagnostics Report Years Considered
Figure 12. Global Non-Invasive Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Non-Invasive Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Non-Invasive Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 15. Global Non-Invasive Cancer Diagnostics Market Share by Players in 2023
Figure 16. Global Top Non-Invasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Invasive Cancer Diagnostics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Non-Invasive Cancer Diagnostics Revenue in 2023
Figure 18. North America Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Non-Invasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 20. United States Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Non-Invasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 24. Germany Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Non-Invasive Cancer Diagnostics Market Share by Region (2019-2030)
Figure 32. China Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Non-Invasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 40. Mexico Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Non-Invasive Cancer Diagnostics Market Share by Country (2019-2030)
Figure 44. Turkey Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Gen-Probe Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 47. Digene Corporation Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 48. Quest Diagnostics Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 49. Cancer, Genetics Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 50. BIOVIEW Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 51. AVIVA Biosciences Corporation Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 52. Laboratory Corporation of America Holdings (LabCorp) Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 53. A&G Pharmaceutical Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 54. Affymetrix Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 55. Precision Therapeutics Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
